RandyW Posted March 5, 2009 Share Posted March 5, 2009 Cellectar gets FDA approval for clinical trials State Journal staff Cellectar, a Madison company developing small molecules to light up tumors and shrink them, has received approval from the U.S. Food and Drug Administration to begin studies in patients this year, the company announced Tuesday. Two phase 1 studies at four medical centers will evaluate appropriate doses of CLR 1404, which is designed for patients with advanced solid-tumor cancers. The studies are expected to begin by June, Cellectar said. Jamey Weichert, a UW-Madison chemist and co-founder of Cellectar, has said the drug could help patients with lung, prostate and pancreatic cancers. Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.